AbbVie Celebrates Launch as New Biopharmaceutical Company with Employees, Patients

AbbVie Celebrates Launch as New Biopharmaceutical Company with Employees, 
NEW YORK, Jan. 2, 2013 /CNW/ - AbbVie (NYSE:ABBV) today marks its launch as an 
independent biopharmaceutical company, with employees from more than 40 
countries and patients joining AbbVie leaders as they ring the first opening 
bell of 2013 at the New York Stock Exchange. 
To view the multimedia assets associated with this release, please click:
With a rich, 125-year heritage of developing pharmaceuticals, AbbVie combines 
the focus and passion of a leading-edge biotech with the expertise and 
structure of a long-established pharmaceutical leader. A global enterprise 
that serves patients in more than 170 countries, AbbVie launches with an 
estimated $18 billion in annual revenues and a strong commitment to creating 
shareholder value through long-term growth potential and the continuation of 
the company's history of shareholder dividends. 
"Today AbbVie launches with an outstanding portfolio, a solid pipeline and 
enthusiastic people who will serve patients and deliver growth," said Richard 
A. Gonzalez, Chairman of the Board and Chief Executive Officer, AbbVie. "With 
those assets and a relentless focus on innovation we intend to create 
significant value for our shareholders." 
Strong, Well-Managed Business and Product Portfolio AbbVie launches with a 
team of experienced senior leaders who understand how to manage AbbVie for 
long-term, profitable growth and who have the proven ability to commercialize 
scientific discoveries for patients. As a biopharmaceutical company, AbbVie 
has adopted a streamlined and focused business model built on a broad 
portfolio of market leading medicines that will enable AbbVie to invest in 
tomorrow's therapies. 
The portfolio includes both growth brands and durable performers, including 
HUMIRA, AndroGel, Lupron, Synagis[1], Creon, Synthroid, Kaletra, Norvir and 
Related information: 
AbbVie's long-term growth will be fueled by a compelling pipeline of more than 
20 mid- to late-stage clinical programs – as well as new discoveries to 
address diseases including Hepatitis C, rheumatoid arthritis, psoriasis, 
multiple sclerosis, Alzheimer's disease, Parkinson's disease, 
spondyloarthropathies, multiple myeloma and endometriosis. AbbVie has tripled 
the number of new molecular entities in its pipeline over the last several 
With these and other compounds in its pipeline, AbbVie is rapidly developing 
therapies that have strong clinical performance, patient benefit and health 
economic value. 
Related information: 
AbbVie's Approach to Innovation Making new discoveries and developing them 
into effective medicines is the foundation of the company's mission and 
business. To accomplish those goals, AbbVie's research is guided by a 
patient-driven research and development (R&D) approach that begins with a deep 
understanding of the serious diseases that are the company's focus, as well as 
careful evaluation of the current needs of patients, payers and regulators 
worldwide. The company's scientists and physicians focus their work on targets 
that have the best potential to fundamentally transform the way diseases are 
treated in the future. 
AbbVie is committed to an agile and collaborative approach to innovation, 
across its global R&D and manufacturing sites. The company's scientists rely 
on proprietary technologies and methods to help them more quickly advance the 
most promising compounds from laboratory to clinical trials. AbbVie's research 
operates with a collaborative model that seeks to build the pipeline of 
discoveries from inside and outside the company's own walls. 
Related information: 
A Focus on Patients AbbVie is focused on developing specialty pharmaceuticals 
that address complex, unsolved health problems, particularly chronic diseases, 
that now account for 75 percent of all healthcare costs. By developing new 
specialty treatments that improve patient outcomes, AbbVie and its people are 
helping to reduce the long-term health and economic impact of these conditions. 
Related information: 
Dedicated Employees to Build the Future AbbVie's 21,000 employees around the 
world are dedicated to meeting the needs of patients. They have the freedom, 
expertise, and ability to innovate and discover solutions to the world's most 
pressing health needs. 
"Our commitment at AbbVie is to build on Abbott's 125-year heritage and 
address some of the world's most serious health issues," Gonzalez said. "We 
intend AbbVie's enduring legacy to be one of finding treatments for patients 
with serious health care needs." 
AbbVie will be listed on the NYSE and NYSE Euronext Paris beginning today 
under the ticker symbol "ABBV". A live webcast of the Opening Bell, beginning 
today at 9:29 a.m. EST, will be available on the NYSE website.  Photos and an 
archived video of the bell ringing will be available on Facebook (NYSE 
Euronext-Official Site), YouTube (nysetv1), and Twitter (@NYSEEuronext), 
AbbVie Facts 

    --  Corporate Headquarters: North Chicago, Illinois, USA
    --  Executive Leadership Team:
        o Richard A. Gonzalez, Chairman of the Board and Chief
          Executive Officer
        o Laura J. Schumacher, Executive Vice President, Business
          Development, External Affairs and General Counsel
        o William J. Chase, Executive Vice President, Chief Financial
        o Carlos Alban, Executive Vice President, Commercial Operations
        o John M. Leonard, M.D., Senior Vice President, Chief
          Scientific Officer
        o Timothy J. Richmond, Senior Vice President, Human Resources

Becoming AbbVie AbbVie (NYSE:ABBV) is a global, research-based 
biopharmaceutical company formed in 2013 following separation from Abbott. 
AbbVie combines the focus and passion of a leading-edge biotech with the 
expertise and structure of a long-established pharmaceutical leader. The 
company's mission is to use its expertise, dedicated people and unique 
approach to innovation to develop and market advanced therapies that address 
some of the world's most complex and serious diseases.

AbbVie aims to help patients live healthier lives and collaborate on 
sustainable healthcare solutions. In 2013, AbbVie will employ approximately 
21,000 people worldwide and market medicines in more than 170 countries. For 
further information on the company and its people, portfolio and commitments, 
please visit Follow @abbvie on Twitter or view careers on our 
Facebook or LinkedIn page.

Forward-Looking Statements Some statements in this news release may be 
forward-looking statements for purposes of the Private Securities Litigation 
Reform Act of 1995. AbbVie cautions that these forward-looking statements are 
subject to risks and uncertainties that may cause actual results to differ 
materially from those indicated in the forward-looking statements. Economic, 
competitive, governmental, technological and other factors that may affect 
AbbVie's operations are discussed in the "Risk Factors" section of the 
Information Statement attached to our Form 10 Registration Statement, which 
has been filed with the SEC, and are incorporated by reference.  AbbVie 
undertakes no obligation to release publicly any revisions to forward-looking 
statements as a result of subsequent events or developments, except as 
required by law.

Media: Greg Miley (847) 938-4898 

Adelle Infante (847) 938-8745

Investors: Larry Peepo  (847) 935-6722

Liz Shea (847) 935-2211

[1] Synagis is a trademark of MedImmune


To view this news release in HTML formatting, please use the following URL:

CO: AbbVie
ST: New York

-0- Jan/02/2013 13:01 GMT

Press spacebar to pause and continue. Press esc to stop.